Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | EGFR | P00533 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | CCR8 | P51685 | 1/20 | 0.50 |
| ▸ | LTA4H | P09960 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27377437 | 1.00 | PKM (0.55) | PKMNPSR1MEN1KMT2APOLB | |
| SCHEMBL17103461 | 1.00 | PKM (0.55) | PKMNPSR1MEN1KMT2APOLB | |
| SCHEMBL8350324 | 0.88 | PKM (0.49) | PKMNPSR1MEN1KMT2APOLB | |
| SCHEMBL8351735 | 0.88 | PKM (0.49) | PKMNPSR1MEN1KMT2APOLB | |
| SCHEMBL2605500 | 0.88 | PKM (0.49) | PKMNPSR1MEN1KMT2APOLB | |
| SCHEMBL15511981 | 0.87 | ALDH1A1 (0.52) | PKMNPSR1MAPTALDH1A1NPC1 | |
| SCHEMBL13470194 | 0.87 | ALDH1A1 (0.52) | PKMNPSR1MAPTALDH1A1NPC1 | |
| SCHEMBL20501772 | 0.87 | ALDH1A1 (0.52) | PKMNPSR1MAPTALDH1A1NPC1 | |
| SCHEMBL16761796 | 0.86 | KMT2A (0.63) | MEN1KMT2APOLBMAPTKDM4E | |
| SCHEMBL6172918 | 0.86 | KMT2A (0.63) | MEN1KMT2APOLBMAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4608810-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF USE TO TREAT HYPOPARATHYROIDISM AND OSTEOPOROSIS | Septerna, Inc. (US) | 2025-09-03 | — | — | EP | disclosed |
| WO-2024091498-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF USE TO TREAT HYPOPARATHYROIDISM AND OSTEOPOROSIS | SEPTERNA, INC. (US) | 2024-05-02 | — | — | WO | disclosed |
| US-20220242886-A1 | CHEMICAL COMPOUNDS | CANAAN XII L.P. | 2022-08-04 | — | — | US | disclosed |
| US-20220242886-A1 | CHEMICAL COMPOUNDS | CANAAN XII L.P. | 2022-08-04 | — | — | US | disclosed |
| US-11306108-B2 | Chemical compounds | BORAH, INC. (US) | 2022-04-19 | — | — | US | disclosed |
| EP-3969458-A1 | CHEMICAL COMPOUNDS | Boragen, Inc. (US) | 2022-03-23 | — | — | EP | disclosed |
| US-20210188879-A1 | CHEMICAL COMPOUNDS | CANAAN XII L.P. | 2021-06-24 | — | — | US | disclosed |
| WO-2020232470-A1 | CHEMICAL COMPOUNDS | Boragen, Inc. (US) | 2020-11-19 | — | — | WO | disclosed |
| US-10370375-B2 | Heterocyclyl-substituted cyclohexylsulfonamides as JAK inhibitors | ELANCO TIERGESUNDHEIT AG (US) | 2019-08-06 | — | — | US | disclosed |
| US-20180346465-A1 | New Compounds | ELANCO TIERGESUNDHEIT AG (US) | 2018-12-06 | — | — | US | disclosed |
| EP-3122731-B1 | CYCLOHEXYLMETHANSULFONAMIDES | ELANCO TIERGESUNDHEIT AG (CH) | 2018-10-10 | — | — | EP | disclosed |
| US-10059709-B2 | Compounds | ELANCO TIERGESUNDHEIT AG (CH) | 2018-08-28 | — | — | US | disclosed |
| US-20170050965-A1 | New Compounds | ELANCO TIERGESUNDHEIT AG (CH) | 2017-02-23 | — | — | US | disclosed |
| EP-2924026-A1 | Aminosulfonylmethylcyclohexanes as JAK inhibitors | Novartis Tiergesundheit AG (CH) | 2015-09-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180346465-A1 | New Compounds | HLA-DRB1, SLC10A1, NFATC1 | PKM 2255/4885NPSR1 1669/4885MEN1 69/4885 |
| US-10370375-B2 | Heterocyclyl-substituted cyclohexylsulfonamides as JAK inhibitors | JAK1, JAK3, JAK2 | PKM 1499/4885NPSR1 2123/4885MEN1 661/4885 |
| US-20210188879-A1 | CHEMICAL COMPOUNDS | JAK2, JAK1, JAK3 | PKM 1051/4885NPSR1 2505/4885MEN1 1421/4885 |
| US-20170050965-A1 | New Compounds | HLA-DRB1, SLC10A1, NFATC1 | PKM 2258/4885NPSR1 1654/4885MEN1 70/4885 |
| US-20220242886-A1 | CHEMICAL COMPOUNDS | JAK2, JAK1, JAK3 | PKM 1051/4885NPSR1 2505/4885MEN1 1421/4885 |
| US-10059709-B2 | Compounds | HLA-DRB1, SLC10A1, ITCH | PKM 1547/4885NPSR1 1656/4885MEN1 63/4885 |
| US-11306108-B2 | Chemical compounds | JAK2, JAK1, JAK3 | PKM 1051/4885NPSR1 2505/4885MEN1 1421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.